Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1973 Jun;24(6):1035–1040.

Studies in myasthenia gravis

Heat stability and species specificity of active muscle antigens

Allyn H Rule, Y Patricia Bartlett, K E Osserman
PMCID: PMC1422928  PMID: 4197974

Abstract

Both myosin and actomyosin, active antigens related to antibody induction in myasthenia gravis, show different stabilities. With time or increasing heat treatment, myosin rapidly loses antigenic activity. While actomyosin showed lower initial antigenic activity, both with time and various heat treatments it showed greater stability and final activity. Utilization of actomyosin from several animal sources showed antigenic sites were species related. Human, monkey and rabbit actomyosin were good sources of antigen for studies with human myasthenic sera.

Full text

PDF
1035

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarli J. A., Tönder O. Antiglobulin consumption test with sera from patients with myasthenia gravis. Clin Exp Immunol. 1970 Jul;7(1):11–21. [PMC free article] [PubMed] [Google Scholar]
  2. Dreizen P., Gershman L. C. Molecular basis of muscular contraction. Myosin. Trans N Y Acad Sci. 1970 Feb;32(2):170–203. doi: 10.1111/j.2164-0947.1970.tb02052.x. [DOI] [PubMed] [Google Scholar]
  3. NASTUK W. L., PLESCIA O. J., OSSERMAN K. E. Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med. 1960 Oct;105:177–184. doi: 10.3181/00379727-105-26050. [DOI] [PubMed] [Google Scholar]
  4. NASTUK W. L., STRAUSS A. J., OSSERMAN K. E. Search for a neuromuscular blocking agent in the blood of patients with myasthenia gravis. Am J Med. 1959 Mar;26(3):394–409. doi: 10.1016/0002-9343(59)90248-7. [DOI] [PubMed] [Google Scholar]
  5. Osserman K. E., Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med. 1971 Nov-Dec;38(6):497–537. [PubMed] [Google Scholar]
  6. Osserman K. E., Weiner L. B. Studies in myasthenia gravis. Correlation of antibody immunofluorescence with clinical course. N Engl J Med. 1965 Sep 16;273(12):615–620. doi: 10.1056/NEJM196509162731201. [DOI] [PubMed] [Google Scholar]
  7. Rule A. H., Kornfeld P. Studies in myasthenia gravis: biologic aspects. Mt Sinai J Med. 1971 Nov-Dec;38(6):538–572. [PubMed] [Google Scholar]
  8. Soborg M., Bendixen G. Human lymphocyte migration as a parameter of hypersensitivity. Acta Med Scand. 1967 Feb;181(2):247–256. doi: 10.1111/j.0954-6820.1967.tb07255.x. [DOI] [PubMed] [Google Scholar]
  9. Strauss A. J., Kemp P. G., Jr Serum autoantibodies in myasthenia gravis and thymoma: selective affinity for I-bands of striated muscle as a guide to identification of antigen(s). J Immunol. 1967 Nov;99(5):945–953. [PubMed] [Google Scholar]
  10. Vetters J. M. Immunofluorescence staining patterns in skeletal muscle using serum of myasthenic patients and normal controls. Immunology. 1965 Jul;9(1):93–95. [PMC free article] [PubMed] [Google Scholar]
  11. Vetters J. M. Muscle antibodies in myasthenia gravis. Immunology. 1967 Sep;13(3):275–280. [PMC free article] [PubMed] [Google Scholar]
  12. YASUI T., HASIMOTO Y., TONOMURA Y. Physicochemical studies on denaturation of myosin-adenosinetriphosphatase. Arch Biochem Biophys. 1960 Mar;87:55–62. doi: 10.1016/0003-9861(60)90122-3. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES